Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Inspire Medical Systems (INSP)

Inspire Medical Q4 revenue up 25%; 2025 revenue guidance $940 million to $955 million

Positive Impact 4 of 5 earnings Written later

Inspire Medical Systems reported preliminary, unaudited fourth-quarter 2024 revenue of $239.5 million to $239.7 million, about 25% higher than a year earlier, and full-year 2024 revenue of $802.6 million to $802.8 million, up about 28%. The company also gave initial 2025 revenue guidance of $940 million to $955 million, a 17% to 19% increase, and announced leadership changes, including a new Chief Manufacturing and Quality Officer. The figures are estimates that may change before the full 2024 results are reported in the Form 10-K.

Key points

  • Preliminary Q4 2024 revenue of $239.5 million to $239.7 million, up about 25% year over year
  • Preliminary full-year 2024 revenue of $802.6 million to $802.8 million, up about 28%
  • Initial 2025 revenue guidance of $940 million to $955 million, a 17% to 19% increase
  • Jason Kelly named Chief Manufacturing and Quality Officer effective January 20, 2025; Chief Medical Officer Charisse Sparks left the company at the beginning of 2025

The filing

CompanyInspire Medical Systems (INSP)
Form8-K, current report
Filed with the SECJan 13, 2025, 6:48 AM ET
Accession number0001609550-25-000003

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.